Published in Cancer on February 01, 1987
Bacillus Calmette-Guerin (BCG) enhances monocyte- and lymphocyte-mediated bladder tumour cell killing. Br J Cancer (1995) 0.89
p53 immunohistochemistry as an independent prognostic factor for superficial transitional cell carcinoma of the bladder. Br J Cancer (1995) 0.85
Classification and grading of the non-invasive urothelial neoplasms: recent advances and controversies. J Clin Pathol (2003) 0.83
Intracavitary prophylactic treatment with interferon alpha 2b of patients with superficial bladder cancer is associated with a systemic T-cell activation. Br J Cancer (1994) 0.78
Prophylactic intracavitary treatment with interferon alpha increases interferon gamma production by peripheral blood mononuclear cells in patients with superficial transitional cell carcinoma of the bladder. Br J Cancer (1997) 0.78
A macrophage factor inhibits adipocyte gene expression: an in vitro model of cachexia. Science (1985) 4.98
Curcumin: from ancient medicine to current clinical trials. Cell Mol Life Sci (2008) 4.24
The molecular cloning and characterization of murine ferritin heavy chain, a tumor necrosis factor-inducible gene. J Biol Chem (1988) 2.15
Hormonal risk factors in testicular cancer. A case-control study. Am J Epidemiol (1986) 1.97
Development of the human gastrointestinal tract. A review. Gastroenterology (1976) 1.93
Ferritin and the response to oxidative stress. Biochem J (2001) 1.88
Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein. Cancer Chemother Pharmacol (1997) 1.73
A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. J Urol (1996) 1.69
Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study. J Clin Oncol (1985) 1.65
Role for NF-kappa B in the regulation of ferritin H by tumor necrosis factor-alpha. J Biol Chem (1995) 1.61
Doxorubicin selectively inhibits muscle gene expression in cardiac muscle cells in vivo and in vitro. Proc Natl Acad Sci U S A (1990) 1.59
Coordinate transcriptional and translational regulation of ferritin in response to oxidative stress. Mol Cell Biol (2000) 1.58
Response of hormone refractory prostate cancer to lycopene. J Urol (2001) 1.40
Comparison and validation of limited sampling equations for cyclosporine area-under-the-curve monitoring calculations in pediatric renal transplant recipients. Ther Drug Monit (1997) 1.39
Iron-independent induction of ferritin H chain by tumor necrosis factor. Proc Natl Acad Sci U S A (1991) 1.36
Expression of 92-kD type IV collagenase/gelatinase (gelatinase B) in osteoarthritic cartilage and its induction in normal human articular cartilage by interleukin 1. J Clin Invest (1993) 1.36
Tumor necrosis factor inhibits human myogenesis in vitro. Mol Cell Biol (1988) 1.35
Bladder cancer, 1996. CA Cancer J Clin (1996) 1.32
Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. J Clin Oncol (1994) 1.25
Determination of GDC-0449, a small-molecule inhibitor of the Hedgehog signaling pathway, in human plasma by solid phase extraction-liquid chromatographic-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2010) 1.20
Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Assessment by endomyocardial biopsy. Ann Intern Med (1983) 1.19
The biology and treatment of superficial bladder cancer. J Clin Oncol (1984) 1.18
Cardiotoxicity of epirubicin and doxorubicin: assessment by endomyocardial biopsy. Cancer Res (1986) 1.17
Recombinant ferritin: modulation of subunit stoichiometry in bacterial expression systems. Protein Eng (1997) 1.13
Interleukin 1 induces ferritin heavy chain in human muscle cells. Biochem Biophys Res Commun (1990) 1.12
Brain metastases from transitional cell carcinoma of the bladder. J Urol (1988) 1.10
FER-1, an enhancer of the ferritin H gene and a target of E1A-mediated transcriptional repression. Mol Cell Biol (1995) 1.08
Role of H and L subunits in mouse ferritin. J Biol Chem (1996) 1.07
A comparison of the quality of participation of community affiliates and that of universities in the Northern California Oncology Group. J Clin Oncol (1983) 1.07
Tumor necrosis factor-alpha and interleukin 1-alpha regulate transferrin receptor in human diploid fibroblasts. Relationship to the induction of ferritin heavy chain. J Biol Chem (1991) 1.06
Interleukin-1 beta induces interleukin-1 receptor antagonist and tumor necrosis factor binding protein in humans. Cancer Res (1993) 1.02
Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance. J Clin Oncol (1992) 1.01
Weekly doxorubicin in endocrine-refractory carcinoma of the prostate. J Clin Oncol (1983) 0.99
p53-independent apoptosis mediated by tachpyridine, an anti-cancer iron chelator. Carcinogenesis (2001) 0.98
Evidence for two mechanisms by which tumor necrosis factor kills cells. J Biol Chem (1989) 0.98
Tumor cell cytotoxicity of a novel metal chelator. Blood (1998) 0.95
Serum markers in germ cell neoplasms. Hematol Oncol Clin North Am (1991) 0.95
Iron and ferritin in inflammation and cancer. Adv Inorg Biochem (1994) 0.95
Preferential repression of the H subunit of ferritin by adenovirus E1A in NIH-3T3 mouse fibroblasts. J Biol Chem (1993) 0.94
Role of protein phosphorylation in TNF-induced apoptosis: phosphatase inhibitors synergize with TNF to activate DNA fragmentation in normal as well as TNF-resistant U937 variants. J Cell Biochem (1993) 0.94
Extralymphatic Hodgkin's disease. Prognosis and response to therapy. Am J Med (1981) 0.93
Long-term results of irradiation for patients with progressive Graves' ophthalmopathy. Int J Radiat Oncol Biol Phys (2001) 0.92
Preliminary observations of intraperitoneal carboplatin pharmacokinetics during a phase I study of the Northern California Oncology Group. Cancer Chemother Pharmacol (1986) 0.92
Patterns of failure in small cell carcinoma of the lung. Cancer (1982) 0.92
Human H-kininogen is a ferritin-binding protein. J Biol Chem (1998) 0.92
Activation of the ferritin H enhancer, FER-1, by the cooperative action of members of the AP1 and Sp1 transcription factor families. J Biol Chem (1998) 0.91
Transcriptional regulation of the mouse ferritin H gene. Involvement of p300/CBP adaptor proteins in FER-1 enhancer activity. J Biol Chem (1999) 0.91
Evaluation of three manual drug information retrieval systems for investigational antineoplastic drugs. Drug Intell Clin Pharm (1987) 0.91
Absolute bioavailability and absorption characteristics of aerosolized tobramycin in adults with cystic fibrosis. J Clin Pharmacol (1994) 0.91
Adenovirus E1A blocks oxidant-dependent ferritin induction and sensitizes cells to pro-oxidant cytotoxicity. FEBS Lett (1999) 0.91
A phase I single-dose trial of gadolinium texaphyrin (Gd-Tex), a tumor selective radiation sensitizer detectable by magnetic resonance imaging. Clin Cancer Res (1999) 0.90
The fate of the bladder in patients with metastatic bladder cancer treated with cisplatin, methotrexate and vinblastine: a Northern California Oncology Group study. J Urol (1985) 0.88
Cisplatin, methotrexate and vinblastine plus surgical restaging for patients with advanced transitional cell carcinoma of the urothelium. J Urol (1993) 0.88
Pharmacological considerations in the modulation of multidrug resistance. Eur J Cancer (1996) 0.88
The chemotherapy of prostatic adenocarcinoma. Ann Intern Med (1980) 0.87
Reversal by cefoperazone of resistance to etoposide, doxorubicin, and vinblastine in multidrug resistant human sarcoma cells. Cancer Res (1989) 0.87
Transitional cell carcinoma of the prostate in patients undergoing radical cystoprostatectomy. J Urol (1992) 0.86
Efficient scheduling of cystoscopies in monitoring for recurrent bladder cancer. Med Decis Making (1989) 0.86
Regulation of NF-kappaB and HIV-1 LTR activity in mouse L cells by ultraviolet radiation: LTR trans-activation in a nonirradiated genome in heterokaryons. Exp Cell Res (1997) 0.86
Augmentation by IL-1 alpha of tumor necrosis factor-alpha cytotoxicity in cells transfected with adenovirus E1A. J Immunol (1993) 0.86
Tumor necrosis factor-induced c-myc expression in the absence of mitogenesis is associated with inhibition of adipocyte differentiation. Proc Natl Acad Sci U S A (1993) 0.85
The core control system of intracellular iron homeostasis: a mathematical model. J Theor Biol (2012) 0.84
Primary osteogenic sarcoma of the bladder. Case report and review of the literature. Cancer (1986) 0.84
Possible risk of invasive pulmonary aspergillosis with marijuana use during chemotherapy for small cell lung cancer. Drug Intell Clin Pharm (1986) 0.84
Radio frequency ablation of lung metastases from renal cell carcinoma. J Urol (2001) 0.84
Gynecomastia in testicular cancer patients. Prognostic and therapeutic implications. Cancer (1985) 0.84
Adjuvant intravesicular pharmacotherapy for superficial bladder cancer. J Natl Cancer Inst (1991) 0.83
Murine ferritin heavy chain: isolation and characterization of a functional gene. Gene (1990) 0.83
The chemotherapy of bladder carcinoma: systemic therapy. Recent Results Cancer Res (1983) 0.83
Stage T1 bladder cancer: grade is the primary determinant for risk of muscle invasion. J Urol (1991) 0.82
A phase I trial of liposomal doxorubicin, paclitaxel and valspodar (PSC-833), an inhibitor of multidrug resistance. Ann Oncol (2005) 0.82
Prognostic significance of a decline in serum human chorionic gonadotropin levels after initial chemotherapy for advanced germ-cell carcinoma. Ann Intern Med (1984) 0.82
Pharmacokinetic interactions of cyclosporine with etoposide and mitoxantrone in children with acute myeloid leukemia. Leukemia (2002) 0.82
A randomized study of doxorubicin versus doxorubicin plus cisplatin in endocrine-unresponsive metastatic prostatic carcinoma. Cancer (1985) 0.81
Evaluation of mRNA levels by the polymerase chain reaction in small cardiac tissue samples. J Mol Cell Cardiol (1991) 0.80
Development of intestinal adenyl cyclase and its response to cholera enterotoxin. J Clin Invest (1973) 0.80
Response criteria in urologic malignancies. Recent Results Cancer Res (1983) 0.80
Hormonal control of adipocyte differentiation and adipocyte gene expression. Recent Prog Horm Res (1988) 0.80
Superficial bladder cancer: the primacy of grade in the development of invasive disease. J Clin Oncol (1987) 0.80
Clinical reversal of multidrug resistance. Cancer Treat Res (1994) 0.80
Recent advances in the treatment of prostate cancer. Ann Oncol (1999) 0.79
A phase I trial of doxorubicin, paclitaxel, and valspodar (PSC 833), a modulator of multidrug resistance. Clin Cancer Res (2001) 0.79
The role of iron in the cytotoxicity of tumor necrosis factor. Lymphokine Cytokine Res (1993) 0.79
Endocrine therapy of prostate cancer. Cancer Treat Res (1998) 0.79
The use of probenecid as a chemoprotector against cisplatin nephrotoxicity. Cancer (1991) 0.79
Selective inhibition of muscle gene expression by oxidative stress in cardiac cells. J Mol Cell Cardiol (1998) 0.79
Heat localization for targeted tumor treatment with nanoscale near-infrared radiation absorbers. Phys Med Biol (2012) 0.78
A graphic nomogram for warfarin dosage adjustment. Pharmacotherapy (1999) 0.78
Effect of verapamil on doxorubicin cardiotoxicity: altered muscle gene expression in cultured neonatal rat cardiomyocytes. Cancer Res (1993) 0.78
A clinical pharmacy-oriented drug surveillance network: results of a nationwide antibiotic utilization review of bacterial pneumonia--1987. DICP (1989) 0.78
Chemotherapy of advanced transitional cell carcinoma of the uroepithelium. Cancer Chemother Pharmacol (1983) 0.78
Therapeutic approaches including interferon to carcinoma in situ of the bladder. Cancer Treat Rev (1985) 0.78